Harnessing Raman spectroimmunoassay for detection of serological breast cancer markers (Conference Presentation)

Ishan Barman; Ming Li

doi:10.1117/12.2252959

24 April 2017 Harnessing Raman spectroimmunoassay for detection of serological breast cancer markers (Conference Presentation)

Ishan Barman, Ming Li

Author Affiliations +

Proceedings Volume 10077, Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV; 100770N (2017) https://doi.org/10.1117/12.2252959
Event: SPIE BiOS, 2017, San Francisco, California, United States

Abstract

Two critical, unmet needs in breast cancer are the early detection of cancer metastasis and recurrence, and the sensitive assessment of temporal changes in tumor burden in response to therapy. The present research is directed towards developing a non-invasive, ultrasensitive and specific tool that provides a comprehensive real-time picture of the metastatic tumor burden and provides a radically new route to address these overarching challenges. As the continuing search for better diagnostic and prognostic clues has shifted away from a singular focus on primary tumor lesions, circulating and disseminated biomarkers have surfaced as attractive candidates due to the intrinsic advantages of a non-invasive, repeatable “liquid biopsy” procedure. However, a reproducible, facile blood-based test for diagnosis and follow-up of breast cancer has yet to be incorporated into a clinical laboratory assay due to the limitations of existing assays in terms of sensitivity, extensive sample processing requirements and, importantly, multiplexing capability. Here, by architecting nano-structured probes for detection of specific molecular species, we engineer a novel plasmon-enhanced Raman spectroscopic platform that offers a paradigmatic shift from the capabilities of today’s diagnostic test platforms. Specifically, quantitative single-droplet serum tests reveal ultrasensitive and multiplexed detection of three key breast cancer biomarkers, cancer antigen 15-3 (CA15-3), CA27-29 and carcinoembryonic antigen (CEA), over several order of magnitude range of biomarker concentration and clear segmentation of the sera between normal and metastatic cancer levels.

Conference Presentation

Citation Download Citation

Ishan Barman and Ming Li "Harnessing Raman spectroimmunoassay for detection of serological breast cancer markers (Conference Presentation)", Proc. SPIE 10077, Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV, 100770N (24 April 2017); https://doi.org/10.1117/12.2252959

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
PRESENTATION

WATCH
PRESENTATION SAVE TO MY LIBRARY

GET CITATION

KEYWORDS

Breast cancer

Raman spectroscopy

Cancer

Tumors

Multiplexing

Biopsy

Diagnostics

Show All Keywords

Keywords/Phrases

Search In:

Publication Years